Gilead Sciences, INC Schedule 13G passive stakes

Vanguard Capital Management has filed a Schedule 13G reporting a 7.51% beneficial ownership stake in Gilead Sciences Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Gilead Sciences Inc. following an internal realignment.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% through a series of share issuances and pre-funded warrants.

Gilead Sciences, Inc. has reported a complete divestment of its beneficial ownership in Cypherpunk Technologies Inc., holding 0% of common stock.

FMR LLC and Abigail P. Johnson have disclosed a 5.3% beneficial ownership stake in Gilead Sciences Inc. common stock.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% of common stock, holding over 10.6 million shares.

Capital World Investors has filed an amended Schedule 13G, confirming a 4.3% beneficial ownership stake in Gilead Sciences, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 16 to its Schedule 13G, disclosing a passive beneficial ownership of 8.2% in Gilead Sciences Inc. common stock as of March 31, 2025.

Gilead Sciences, Inc. has filed an amended Schedule 13G, disclosing a 3.9% beneficial ownership stake in Kalaris Therapeutics, Inc., which recently completed a merger and changed its name and ticker symbol.

Gilead Sciences, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 3.6% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.